| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Phytic acid targets multiple pathways. It chelates essential minerals such as calcium, iron, and zinc. It acts as a potent antioxidant. It has anti-cancer, anti-inflammatory, and anti-diabetic properties. It can act as a cofactor in DNA repair by nonhomologous end-joining. It inhibits cell differentiation and cell proliferation.
|
|---|---|
| ln Vitro |
With an IC50 of about 30 mM, phytotic acid (inositol) inhibits the production of uric acid from xanthine. Phytic acid has a significant effect on superoxide formation; the IC50 is approximately 6 mM, suggesting that the XO domain that generates superoxide is more susceptible to phytic acid [3].
In vitro, Phytic acid has been shown to have antineoplastic action in colon carcinogenesis. It inhibits cell differentiation and cell proliferation. It has anti-inflammatory and anti-diabetic properties. Quantitative IC50 values for its effects are not detailed in the publicly available sources. |
| ln Vivo |
In vivo, Phytic acid has been shown to have antineoplastic action in colon carcinogenesis. It has anti-inflammatory and anti-diabetic properties. As a natural compound found in foods, it is consumed in the diet and has various health effects. Detailed dose-response and pharmacokinetic data in animal models are limited.
|
| Enzyme Assay |
For cell-free assays, the antioxidant activity of Phytic acid can be measured using DPPH or ABTS radical scavenging assays. Its metal chelating activity can be assessed by measuring its ability to chelate iron or other metal ions using colorimetric assays. Its anti-inflammatory activity can be assessed by measuring its inhibition of inflammatory enzymes.
|
| Cell Assay |
For in vitro cellular assays, the anti-cancer activity of Phytic acid is assessed in cancer cell lines by measuring cell viability using MTT or SRB assays. Its anti-inflammatory activity is assessed in LPS-stimulated macrophages by measuring cytokine production. Its effect on cell differentiation and proliferation can be assessed in appropriate cell models.
|
| Animal Protocol |
For in vivo studies, Phytic acid can be administered orally in animal models of cancer, inflammation, or diabetes. In cancer models, endpoints include tumor incidence and growth. In inflammation models, endpoints include inflammatory cytokine levels and tissue histopathology. In diabetes models, endpoints include blood glucose levels and insulin sensitivity.
|
| ADME/Pharmacokinetics |
Phytic acid (CAS 83-86-3) has a molecular formula of C6H18O24P6 and a molecular weight of 660.04 g/mol. It is also known as inositol hexaphosphate (IP6). Appearance:淡黄色至淡褐色浆状液体 (light yellow to light brown syrupy liquid). Solubility: soluble in water, ethanol, and acetone; almost insoluble in ether, benzene, and chloroform. Storage: typical for organic acids (cool, dark place). Purity: typically 50-70% in water for commercial solutions.
|
| Toxicity/Toxicokinetics |
Phytic acid has low toxicity. It is a natural compound found in foods and is generally recognized as safe (GRAS). However, high doses can chelate essential minerals and may lead to deficiencies.
|
| References | |
| Additional Infomation |
Inositol hexaphosphate is an inositol hexaphosphate derivative in which each hydroxyl group of inositol is monophosphorylated. It has multiple functions, including as an iron chelator, antitumor agent, signaling molecule, E. coli metabolite, mouse metabolite, and cofactor. It is the conjugate acid of inositol hexaphosphate (12-). Phytic acid is being investigated in the clinical trial NCT01000233 (Value of Oral Phytic Acid (InsP6) in the Prevention of Cardiovascular Calcification Progression). Inositol hexaphosphate is a metabolite found or produced in E. coli (K12 strain, MG1655 strain). Phytic acid has also been reported in soybeans, corn, and other organisms with relevant data. Inositol hexaphosphate is a metabolite found or produced in Saccharomyces cerevisiae. It can be used as a chelating agent to remove trace heavy metal ions and also has calcium-lowering effects.
Phytic acid is a research-grade compound and is not a drug. It is used as an antioxidant, chelating agent, and preservative in cosmetics, pharmaceuticals, and food. It has been studied for its potential therapeutic applications in cancer, inflammation, and diabetes. No clinical trials have been reported for therapeutic use. |
| Molecular Formula |
C6H18O24P6
|
|---|---|
| Molecular Weight |
660.0353
|
| Exact Mass |
659.861
|
| CAS # |
83-86-3
|
| Related CAS # |
Phytic acid dodecasodium hydrate;123408-98-0;Zinc Phytate;63903-51-5;Phytic acid sodium salt;14306-25-3;Calcium Phytate;3615-82-5;Phytic acid hexasodium;34367-89-0
|
| PubChem CID |
890
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
2.4±0.1 g/cm3
|
| Boiling Point |
1190.7±75.0 °C at 760 mmHg
|
| Flash Point |
673.9±37.1 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
-8.47
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
36
|
| Complexity |
818
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([C@@H]1[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O)P(O)(O)=O
|
| InChi Key |
IMQLKJBTEOYOSI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H18O24P6/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24)
|
| Chemical Name |
(2,3,4,5,6-pentaphosphonooxycyclohexyl) dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~151.51 mM)
H2O : ≥ 30 mg/mL (~45.45 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5151 mL | 7.5753 mL | 15.1506 mL | |
| 5 mM | 0.3030 mL | 1.5151 mL | 3.0301 mL | |
| 10 mM | 0.1515 mL | 0.7575 mL | 1.5151 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
